ZLDPF Zealand Pharma A/S

Zealand Pharma to participate in the Jefferies Global Healthcare Conference

Zealand Pharma to participate in the Jefferies Global Healthcare Conference

Press release – No. 16 / 2025

Zealand Pharma to participate in the Jefferies Global Healthcare Conference

Copenhagen, Denmark, November 12, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 10:30am GMT (11:30am CET) on Wednesday, November 19, 2025.

A live audio webcast of the fireside chat will be available at , and accessible through the company’s website at , where a recording of the webcast will also be archived after the event.

About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Zealand Pharma

Email:

Neshat Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Email:

Rachel James-Owens (Media)

Vice President, Corporate Communications & Media Relations

Zealand Pharma

Email:



EN
12/11/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma to participate in upcoming investor conferences in Marc...

Zealand Pharma to participate in upcoming investor conferences in March 2026 Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026. 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami Adam Steensberg, President and Chief Executive Officer, will host investor meetings...

March 9, 2026 1 EN
BC-bc user ... (+8)
  • BC-bc user
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi
COMB Compagnie du Bo...
JEN JENSEN-GROUP ... (+9)

Morning Notes : ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, H...

: ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, HYSG BB, ZEAL DC, ECMPA NA

COMB COMPAGNIE DU BOIS SAUVAGE SA
JEN JENSEN-GROUP
ELI ELIA GROUP SA/NV
ZLDPF ZEALAND PHARMA A/S
BPOST BPOST SA
ATEB ATENOR S.A.
GLOG GLOBAL GRAPHICS S.A.
GLPG GALAPAGOS NV
ECMPA EUROCOMMERCIAL PROPERTIES NV
03/06/26 March 6, 2026 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Petrelintide shows modest weight loss but excellent tol...

Zealand reported mixed results from the phase 2 (ZUPREME-1) trial of petrelintide in overweight/obesity, showing a modest 10.7% weight loss at 42 weeks, while demonstrating excellent tolerability. We think this outcome makes first line positioning difficult, and view petrelintide as better suited for weight loss maintenance (subject to positive data in that setting). We adjust our peak sales estimate to $ 7b (from $ 22b), which brings down our TP to DKK 500 (from DKK 960). Given the lower upside...

ZLDPF ZEALAND PHARMA A/S
03/06/26 March 6, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma announces positive Phase 2 results for petrelintide, an...

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, the...

March 5, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma convenes its Annual General Meeting 2026

Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch